We are investigating whether weekly doses of GLM101 can improve movement and coordination in people with PMM2-CDG. The study will also evaluate the safety of this new treatment compared to a placebo.
Health conditions and diseases that the clinical trial is designed to study and treat.
Congenital Disorder of Glycosylation (CDG) is a rare genetic condition that affects the body's ability to properly modify proteins, leading to a variety of symptoms including developmental delays and neurological issues.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
